Abris Capital sells Scanmed
Abris sells Scanmed, the leading privately owned, diversified in-patient care provider in Poland
We are excited to announce that on December 12, 2024, Abris Capital Partners (“Abris”), finalized the sale of Scanmed Group to American Heart of Poland.
Abris invested in Scanmed Group in 2020. Scanmed is the leading, private provider of high-quality healthcare services, offering a wide range of medical services within primary care, outpatient specialist consultations, diagnostics and inpatient/hospital treatment. It operates in over 30 locations, treating almost 500,000 patients annually throughout Poland.
Scanmed runs four multi-specialist hospitals: St. Raphael Hospital in Krakow, Rudolf Weigl Hospital in Blachownia, Vital Medic in Kluczbork and Ars-Medical in Piła,
13 cardiac cath labs and three specialized in-patient clinics in gastroenterology, ophthalmology and orthopedics.
Wojciech Łukawski, Partner at Abris Capital Partners comments: It’s been a privilege to work with Scanmed’s highly skilled and experienced managers and top-notch medical team. We are proud of the fact how significantly the company developed with the support of the Abris professionals, growing the scale of the operation and increasing the quality of services provided to patients. We firmly believe that after the acquisition by American Heart of Poland and operating as part of the leading European healthcare group, Scanmed will continue to be the vital element of the Polish healthcare system, offering patients the highest quality treatment.
American Heart of Poland, provides comprehensive, multi-specialized medical care, combining health education, prevention, diagnosis, treatment, and rehabilitation. The group operates through over 20 medical centers and treats over 260,000 patients annually offering them access to high-class medical procedures.
American Heart of Poland is controlled by Gruppo San Donato – the leading European healthcare group specialising in acute care, medical education and research. With 136 medical facilities, world leading teaching and research hospitals, university as well as medical research ranking top 10 globally (by medical research citations), Gruppo San Donato is the pioneer of gene and cell therapy globally. GSD treats over 5.8 million patients in a year and employs over 28,000 medical professionals.